A Phase I/Ib, Multicenter, Open-Label, Dose-Escalation Study of FT-2102 as a Single agent and in Combination with Azacitidine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
FORMA Therapeutics, Inc.
Start Date
January 30, 2018
End Date
February 14, 2023
Administered By
Duke Cancer Institute
Awarded By
FORMA Therapeutics, Inc.
Start Date
January 30, 2018
End Date
February 14, 2023